Children are far more likely to die from the vaccine shot than the COVID-19 virus.
In their original submission, Pfizer admitted their products are a gene therapy and not a vaccine. They stated it’s experimental with many unknown causes of harm. They expressed doubt about getting approval due to international regulatory requirements. Mainstream media failed to report this.
As early as July 21, 2021, Dr. Michael Yeadon, a former executive at Pfizer revealed that children are at least 50 times more likely to die from the coronavirus (COVID-19) vaccine than from the virus itself. Corporate media failed to report this.
Almost a year later, Dr. Yeadon’s original calculations may have been very low as they came about as Pfizer was testing its mRNA vaccine on children younger than 12 years old, including 6-month-old babies.
Now, he and other professionals realize they underestimated the dangers of the vaccines on children.
Yeadon, former vice president and chief scientist for allergy and respiratory at Pfizer, has repeatedly stressed that the vaccines have not been adequately tested and that they shouldn’t have received emergency use authorization when there are safe and effective medicines available for COVID-19.
Here is page 7 of Pfizer’s BioNTech original 2021 registration filing:
“No mRNA immunotherapy has been approved, and none may never be approved, in this new potential category of therapeutics,” Pfizer warned at the outset. “mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics.”
“Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following market approval, if any.”
🔹Pfizer and its German partner BioNTech failed to thoroughly examine biodistribution and pharmacokinetics issues related to their experimental gene therapy injection prior to their 2021 submition to the European Medicines Agency (EMA) for review.
🔹Pfizer cut corners and used a “surrogate” mRNA injection that produces the luciferase protein rather than the BNT162b2 variety actually being administered to the public.
“No traditional pharmacokinetic or biodistribution studies have been performed with the vaccine candidate BNT162b2,” EMA reviewers acknowledged about Pfizer’s fraudulent actions.
Regulatory documents also reveal that Pfizer failed to follow industry-standard quality management protocols during preclinical toxicology studies of its injection. These key studies did not meet good laboratory practice (GLP).
“Good laboratory practice or GLP is a set of principles intended to assure the quality and integrity of non-clinical laboratory studies used as the basis for research or marketing permits for products regulated by government agencies,” explained The Defender, a newsletter of Children’s Health Defense (CHD).
“The term GLP is most commonly associated with the pharmaceutical industry and the required non-clinical animal testing that must be performed prior to approval of new drug products.”